孕激素单药作为绝经激素治疗的适应证与疗效综述
本叙述性综述总结孕激素单药作为绝经激素治疗的适应证、疗效与局限性,面向有雌激素禁忌的绝经女性。文献检索纳入系统综述、指南、随机对照试验和队列研究。结论认为孕激素单药可有效缓解血管舒缩症状,耐受性良好,但其长期安全性仍需更大规模高质量研究确认。
要点
- 孕激素单药可用于有雌激素禁忌的绝经女性,包括特定妇科恶性肿瘤、既往静脉血栓栓塞和冠心病等。
- 微粒化黄体酮对睡眠质量有额外获益,醋酸炔诺酮可用于骨健康。
- 孕激素单药对情绪影响总体为中性,乳腺癌风险证据尚不明确。
核心结论
- 孕激素单药是一种有效、耐受性良好但尚未被充分认识的治疗选择,适用于有含雌激素绝经激素治疗禁忌的女性。
- 其最佳使用可依据临床情境调整,如微粒化黄体酮用于睡眠障碍,醋酸炔诺酮用于骨健康。
研究设计与样本
- 本叙述性综述通过结构化文献检索,纳入系统综述、指南、随机对照试验和队列研究。
- 评价内容涵盖孕激素单药用于绝经症状管理、骨健康及肿瘤安全性。
主要发现
- 证据支持在具有雌激素特异性禁忌的患者中使用,包括部分低级别子宫内膜间质肉瘤、特定卵巢癌、既往静脉血栓栓塞、冠心病、代偿性肝病和子宫内膜异位症。
- 孕激素单药的禁忌仅限于不明原因异常阴道出血和个人乳腺癌病史,脑膜瘤患者需谨慎使用。
- 口服、肌内注射和经皮制剂均观察到显著的血管舒缩症状缓解效果。
- 微粒化黄体酮对睡眠质量有额外获益,醋酸甲羟孕酮、醋酸甲地孕酮和醋酸炔诺酮等合成孕激素可不同程度保护骨骼。
- 孕激素单药相关乳腺癌风险因研究有限且检验效能不足仍不确定。
关键数值与推荐
- 孕激素单药禁忌为不明原因异常阴道出血和个人乳腺癌病史。
- 脑膜瘤患者需谨慎使用孕激素单药。
- 微粒化黄体酮可用于改善睡眠质量,醋酸炔诺酮可用于骨健康,具有抗肿瘤特性的孕激素可用于激素敏感型肿瘤。
临床怎么用
- 对存在雌激素禁忌的绝经女性,可依据症状和合并症选择不同孕激素单药方案。
- 睡眠障碍为主者可选择微粒化黄体酮,骨健康需求者可选择醋酸炔诺酮。
- 激素敏感型肿瘤患者可考虑具有已知抗肿瘤特性的孕激素。
局限性
- 研究受异质性方法、样本量小以及缺乏当代直接比较孕激素单药与标准绝经激素治疗或非激素替代方案的试验所限。
- 乳腺癌风险因研究有限且检验效能不足仍不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen monotherapy, though historically underutilized, represents a viable alternative in this population. This narrative review summarizes the indications, efficacy, and limitations of progestogen monotherapy as MHT. A structured literature search identified systematic reviews, guidelines, randomized controlled trials, and cohort studies evaluating progestogen monotherapy for menopausal symptom management, bone health, and oncologic safety. Evidence supports its use in patients with contraindications specific to oestrogen, including those with certain gynecologic malignancies (e.g., low-grade endometrial stromal sarcoma, select ovarian cancers), prior venous thromboembolism, coronary artery disease, compensated liver disease, and endometriosis. Contraindications to progestogen monotherapy are limited to unexplained abnormal vaginal bleeding and personal history of breast cancer, with caution utilised in patients with meningioma. Clinical data demonstrate that progestogens provide significant VMS relief, with efficacy observed across oral, intramuscular, and transdermal preparations. Micronized progesterone shows additional benefits for sleep quality, while synthetic progestins such as medroxyprogesterone acetate, megestrol acetate, and norethindrone acetate variably confer bone protection. Effects on mood appear neutral overall. Breast cancer risk associated with progestogen monotherapy remains uncertain due to limited and underpowered studies. Despite promising evidence, research is constrained by heterogeneous methodologies, small sample sizes, and lack of contemporary trials directly comparing progestogen monotherapy with standard MHT or nonhormonal alternatives. In conclusion, progestogen monotherapy is an effective, well-tolerated, and under-recognized therapeutic option for women with contraindications to oestrogen-containing MHT. Its optimal use may be tailored to clinical context: micronized progesterone for sleep disturbance, norethindrone acetate for bone health, or progestins with known antineoplastic properties in hormone-sensitive tumours. Larger, high-quality studies are needed to better define long-term safety and efficacy.
引用
- BJOG:Indications and Efficacy of Progestogen‐Monotherapy as Menopause Hormone Therapy: A Narrative Review
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。